Hepatic safety of antibiotics used in primary care
Top Cited Papers
Open Access
- 17 May 2011
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 66 (7), 1431-1446
- https://doi.org/10.1093/jac/dkr159
Abstract
Antibiotics used by general practitioners frequently appear in adverse-event reports of drug-induced hepatotoxicity. Most cases are idiosyncratic (the adverse reaction cannot be predicted from the drug's pharmacological profile or from pre-clinical toxicology tests) and occur via an immunological reaction or in response to the presence of hepatotoxic metabolites. With the exception of trovafloxacin and telithromycin (now severely restricted), hepatotoxicity crude incidence remains globally low but variable. Thus, amoxicillin/clavulanate and co-trimoxazole, as well as flucloxacillin, cause hepatotoxic reactions at rates that make them visible in general practice (cases are often isolated, may have a delayed onset, sometimes appear only after cessation of therapy and can produce an array of hepatic lesions that mirror hepatobiliary disease, making causality often difficult to establish). Conversely, hepatotoxic reactions related to macrolides, tetracyclines and fluoroquinolones (in that order, from high to low) are much rarer, and are identifiable only through large-scale studies or worldwide pharmacovigilance reporting. For antibiotics specifically used for tuberculosis, adverse effects range from asymptomatic increases in liver enzymes to acute hepatitis and fulminant hepatic failure. Yet, it is difficult to single out individual drugs, as treatment always entails associations. Patients at risk are mainly those with previous experience of hepatotoxic reaction to antibiotics, the aged or those with impaired hepatic function in the absence of close monitoring, making it important to carefully balance potential risks with expected benefits in primary care. Pharmacogenetic testing using the new genome-wide association studies approach holds promise for better understanding the mechanism(s) underlying hepatotoxicity.This publication has 159 references indexed in Scilit:
- Drug‐induced hepatic injury in children: a case/non‐case study of suspected adverse drug reactions in VigiBaseBritish Journal of Clinical Pharmacology, 2010
- Causality assessment in drug-induced liver injury using a structured expert opinion process: Comparison to the Roussel-Uclaf causality assessment methodHepatology, 2010
- Trovafloxacin Enhances TNF-Induced Inflammatory Stress and Cell Death Signaling and Reduces TNF Clearance in a Murine Model of Idiosyncratic HepatotoxicityToxicological Sciences, 2009
- Using controlled clinical trials to learn more about acute drug-induced liver injuryHepatology, 2008
- Cefdinir-Induced Hepatotoxicity: Potential Hazards of Inappropriate Antibiotic UseJournal of General Internal Medicine, 2008
- Identifying genetic risk factors for serious adverse drug reactions: current progress and challengesNature Reviews Drug Discovery, 2007
- Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard Dose in Pulmonary Tuberculosis PatientsAntimicrobial Agents and Chemotherapy, 2007
- Idiosyncratic drug hepatotoxicityNature Reviews Drug Discovery, 2005
- Comparative Tolerability of the Newer Fluoroquinolone AntibacterialsDrug Safety, 1999
- Hepatotoxicity of Antitubercular TreatmentsDrug Safety, 1996